Brief: Aravive Reports Q1 Loss Per Share $0.44

Aravive

06/05/2021 12:52

May 6 (Reuters) - Aravive Inc  ARAV.O :
    * ARAVIVE REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS AND
ANNOUNCES PLANS TO INVESTIGATE  AVB-500 IN CLINICAL TRIAL AS
FIRST-LINE TREATMENT FOR PANCREATIC CANCER
    * Q1 LOSS PER SHARE $0.44
    * Q1 REVENUE $300,000

Source text for Eikon:  ID:nGNX2B61Zz 
Further company coverage:  ARAV.O 

 ((Reuters Messaging: Reuters.Briefs@thomsonreuters.com))